JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Revised definition of 'fever of unknown origin': limitations and opportunities.

AIM: The limitations and opportunities of revised definition of fevers of unknown origin (FUO) in comparison to conventional definition were investigated, and prehospital characteristics of the patients were detailed.

METHOD: The patients were grouped according to both revised and classic definitions of FUO.

RESULTS: Fifty-nine of the 80 patients (74%) met the conventional definition of FUO. Before their admissions, all patients had at least one course of antibiotic therapy. The aetiology was infectious in 52%, autoimmune in 19%, and neoplastic in 17%. In 12% of the cases, the reason for high fever could not be explained. The most common infectious aetiologies were various forms of tuberculosis (12%), brucellosis (12%), salmonella (7%) and malaria (5%). The revised definition inflated the rate of infectious aetiology.

CONCLUSION: A standardized set of diagnostic tools used in this study was suggested. The subjects of FUO series have to be screened for endemic infections.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app